+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
DNA Repair Drugs Market - Global Forecast to 2030- Product Image
DNA Repair Drugs Market - Global Forecast to 2030- Product Image
Sale

DNA Repair Drugs Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5977983
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The DNA Repair Drugs Market grew from USD 9.18 billion in 2024 to USD 9.87 billion in 2025. It is expected to continue growing at a CAGR of 7.25%, reaching USD 13.98 billion by 2030.

Executive Summary: Introduction to the Evolving DNA Repair Drug Landscape

The field of DNA repair therapeutics has entered a pivotal phase, driven by a deeper understanding of genomic integrity and its critical role in combating a spectrum of diseases. Advances in molecular biology and precision medicine have positioned DNA repair drugs at the forefront of innovation, offering new hope for patients with cancer, rare genetic disorders, and other pathologies linked to DNA damage. This executive summary outlines key developments shaping the market, examines regulatory and economic influences, and provides strategic insights for stakeholders seeking to navigate this dynamic landscape. Through the lens of recent breakthroughs and emerging trends, industry leaders will gain a clear perspective on the forces driving growth and can align their strategies to capitalize on evolving opportunities.

Transformative Shifts Reshaping DNA Repair Therapeutics

Over the past decade, the DNA repair sector has experienced transformative shifts that extend from fundamental research to clinical application. Breakthroughs in understanding homologous recombination and non-homologous end joining mechanisms have spurred the development of targeted inhibitors, while advances in base excision repair have opened new avenues for combination therapies. The rise of precision oncology has further accelerated investment in Poly ADP Ribose Polymerase inhibitors, and emerging modalities such as DNA-PK and checkpoint kinase inhibition are catalyzing a wave of novel candidates. Simultaneously, integration of artificial intelligence into drug discovery pipelines has streamlined compound screening and optimized lead selection. Collectively, these shifts are redefining competitive dynamics, prompting established pharmaceutical companies and nimble biotech firms alike to establish strategic partnerships, pursue specialized niches, and leverage real-world evidence to differentiate their portfolios.

Cumulative Impact of U.S. Tariffs on DNA Repair Drugs in 2025

In 2025, new United States tariff policies have exerted a cumulative impact on the supply chain and cost structures of DNA repair drug developers. Increased duties on imported raw materials and specialized reagents have elevated production expenses, prompting refinement of sourcing strategies and local manufacturing initiatives. Concurrently, tariff-induced cost pressures have accelerated negotiations around pricing and reimbursement, influencing contractual terms with hospitals and research centers. Exporting companies have recalibrated their market entry plans, shifting focus toward regions where favorable trade agreements mitigate tariff effects. Despite these challenges, many organizations are turning adversity into opportunity, investing in vertical integration and supply chain resilience to safeguard clinical trial timelines and maintain competitive pricing while preserving margins.

Key Segmentation Insights for Targeted DNA Repair Therapies

Segmentation analysis reveals distinct patterns across multiple dimensions. When classified by drug type, Poly ADP Ribose Polymerase inhibitors such as Niraparib, Olaparib, and Rucaparib have achieved broad clinical validation, while DNA-PK entrants CC-115 and M3814 and checkpoint kinase inhibitors targeting Chk1 and Chk2 are advancing through critical trial phases. Mechanistic segmentation underscores the importance of base excision repair, homologous recombination, mismatch repair, non-homologous end joining, and nucleotide excision repair pathways as therapeutic targets. In application, gene therapy developers are leveraging DNA repair modulators alongside oncological treatment regimens in breast, ovarian, and prostate cancers, as well as exploring indications for rare genetic disorders. Administration routes vary from intravenous and subcutaneous injections to oral formulations tailored for outpatient care. End users span clinics, hospitals, and research centers, reflecting both clinical and investigative demand. The therapeutic context extends across chemotherapy enhancers, radiation therapy adjuvants, and surgical oncology support, while development stages range from preclinical validation through Phase I, II, and III trials. Finally, chemical form considerations include liquid, lyophilized, and solid presentations, each suited to specific handling and stability requirements.

Key Regional Insights in the Global DNA Repair Drug Market

Regional dynamics are shaping where innovation and adoption occur fastest. In the Americas, robust clinical trial infrastructure and established reimbursement pathways continue to attract investment, making North American hubs critical for late-stage studies and commercial launches. In Europe, Middle East & Africa, supportive regulatory frameworks and collaborative research networks facilitate cross-border partnerships, particularly for rare disease and precision medicine applications. Meanwhile, the Asia-Pacific region has emerged as a high-growth market, driven by expanding healthcare access, government incentives for biotechnology, and a growing base of research centers exploring local patient populations. These regional distinctions inform market entry strategies, licensing agreements, and distribution plans, enabling companies to tailor their approaches to regulatory environments, payer landscapes, and patient demographics.

Key Player Highlights Driving DNA Repair Innovation

The competitive landscape features a blend of established pharma giants and specialized biotech innovators. AstraZeneca PLC and Bristol-Myers Squibb Company have leveraged their oncology portfolios to integrate PARP inhibitors into combination regimens, while Merck KGaA and Pfizer Inc. continue to advance next-generation candidates targeting novel DNA repair nodes. At the same time, Artios Pharma and Valerio Therapeutics are pioneering new modalities in checkpoint kinase and DNA-PK inhibition. Clovis Oncology and Genentech, Inc. have demonstrated commercial success with approved PARP therapies, whereas Eli Lilly and Company and Novartis AG are expanding their pipelines through strategic acquisitions and collaborative research agreements. Companies with strong manufacturing and analytical platforms such as Corden Pharma International GmbH and Bio-Rad Laboratories, Inc. support the industry’s scale-up demands. Meanwhile, Aurigene Discovery Technologies, CanBas Co., Ltd., GlaxoSmithKline PLC, Hanson Wade Group, Johnson & Johnson Services, Inc., and other key players are driving innovation across preclinical and clinical stages, underscoring the sector’s dynamic and competitive nature.

Actionable Recommendations for Industry Leadership in DNA Repair

Industry leaders should prioritize integrated strategies that address both scientific and operational imperatives. First, investing in flexible manufacturing capabilities and establishing regional production hubs will mitigate tariff risks and streamline supply chains. Second, forging alliances with academic institutions and leveraging artificial intelligence-driven discovery platforms can accelerate identification of novel targets and optimize trial design. Third, adopting adaptive clinical trial frameworks will enable faster go/no-go decisions and enhance patient recruitment in niche segments, particularly in rare genetic disorders. Fourth, engaging proactively with payers and health technology assessment bodies in key markets will support favorable reimbursement pathways and ensure rapid patient access. Finally, enhancing portfolio diversification through strategic partnerships and licensing agreements will balance risk across development stages and therapeutic modalities, positioning organizations to capture emerging opportunities in both established and adjacent markets.

Conclusion: Seizing Opportunities in DNA Repair Innovations

The DNA repair drug landscape stands at a crossroads of scientific promise and commercial challenge. By understanding transformative research advances, tariff-driven economic shifts, and segmentation insights, stakeholders can craft informed strategies that optimize development pathways and strengthen market positioning. Collaboration across the value chain-from discovery to commercialization-will be essential to overcome regulatory hurdles and meet the evolving needs of patients and healthcare providers. As competitive dynamics intensify, those who invest in innovation, operational resilience, and strategic partnerships will be best positioned to lead the next wave of breakthroughs in genomic medicine.

Market Segmentation & Coverage

This research report categorizes the DNA Repair Drugs Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Checkpoint Kinase Inhibitors
    • Chk1 Inhibitors
    • Chk2 Inhibitors
  • DNA-PK Inhibitors
    • CC-115
    • M3814
  • Poly ADP Ribose Polymerase (PARP) Inhibitors
    • Niraparib
    • Olaparib
    • Rucaparib
  • Base Excision Repair (BER)
  • Homologous Recombination (HR)
  • Mismatch Repair (MMR)
  • Non-Homologous End Joining (NHEJ)
  • Nucleotide Excision Repair (NER)
  • Clinics
  • Hospitals
  • Research Centers
  • Gene Therapy
  • Oncological Treatment
    • Breast Cancer
    • Ovarian Cancer
    • Prostate Cancer
  • Rare Genetic Disorders
  • Intravenous
  • Oral
  • Subcutaneous
  • Chemotherapy Enhancers
  • Radiation Therapy
  • Surgical Oncology
  • Phase I
  • Phase II
  • Phase III
  • Preclinical
  • Liquid
  • Lyophilized
  • Solid

This research report categorizes the DNA Repair Drugs Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the DNA Repair Drugs Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Artios Pharma
  • AstraZeneca PLC
  • Aurigene Discovery Technologies
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • CanBas Co., Ltd.
  • Clovis Oncology
  • Corden Pharma International GmbH
  • Eli Lilly and Company
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Hanson Wade Group
  • Johnson & Johnson Services, Inc.
  • Merck KgaA
  • Novartis AG
  • Pfizer Inc.
  • Valerio Therapeutics

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. DNA Repair Drugs Market, by Drug Type
8.1. Introduction
8.2. Checkpoint Kinase Inhibitors
8.2.1. Chk1 Inhibitors
8.2.2. Chk2 Inhibitors
8.3. DNA-PK Inhibitors
8.3.1. CC-115
8.3.2. M3814
8.4. Poly ADP Ribose Polymerase (PARP) Inhibitors
8.4.1. Niraparib
8.4.2. Olaparib
8.4.3. Rucaparib
9. DNA Repair Drugs Market, by Mechanism of Action
9.1. Introduction
9.2. Base Excision Repair (BER)
9.3. Homologous Recombination (HR)
9.4. Mismatch Repair (MMR)
9.5. Non-Homologous End Joining (NHEJ)
9.6. Nucleotide Excision Repair (NER)
10. DNA Repair Drugs Market, by End-User
10.1. Introduction
10.2. Clinics
10.3. Hospitals
10.4. Research Centers
11. DNA Repair Drugs Market, by Application
11.1. Introduction
11.2. Gene Therapy
11.3. Oncological Treatment
11.3.1. Breast Cancer
11.3.2. Ovarian Cancer
11.3.3. Prostate Cancer
11.4. Rare Genetic Disorders
12. DNA Repair Drugs Market, by Administration Route
12.1. Introduction
12.2. Intravenous
12.3. Oral
12.4. Subcutaneous
13. DNA Repair Drugs Market, by Therapeutic Area
13.1. Introduction
13.2. Chemotherapy Enhancers
13.3. Radiation Therapy
13.4. Surgical Oncology
14. DNA Repair Drugs Market, by Development Stage
14.1. Introduction
14.2. Phase I
14.3. Phase II
14.4. Phase III
14.5. Preclinical
15. DNA Repair Drugs Market, by Chemical Form
15.1. Introduction
15.2. Liquid
15.3. Lyophilized
15.4. Solid
16. Americas DNA Repair Drugs Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific DNA Repair Drugs Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa DNA Repair Drugs Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Artios Pharma
19.3.2. AstraZeneca PLC
19.3.3. Aurigene Discovery Technologies
19.3.4. Bio-Rad Laboratories, Inc.
19.3.5. Bristol-Myers Squibb Company
19.3.6. CanBas Co., Ltd.
19.3.7. Clovis Oncology
19.3.8. Corden Pharma International GmbH
19.3.9. Eli Lilly and Company
19.3.10. Genentech, Inc.
19.3.11. GlaxoSmithKline PLC
19.3.12. Hanson Wade Group
19.3.13. Johnson & Johnson Services, Inc.
19.3.14. Merck KgaA
19.3.15. Novartis AG
19.3.16. Pfizer Inc.
19.3.17. Valerio Therapeutics
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. DNA REPAIR DRUGS MARKET MULTI-CURRENCY
FIGURE 2. DNA REPAIR DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. DNA REPAIR DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DNA REPAIR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2024 VS 2030 (%)
FIGURE 22. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. DNA REPAIR DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. DNA REPAIR DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DNA REPAIR DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DNA REPAIR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY CHK1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY CHK2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY CC-115, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY M3814, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY NIRAPARIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OLAPARIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY RUCAPARIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BASE EXCISION REPAIR (BER), BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOMOLOGOUS RECOMBINATION (HR), BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MISMATCH REPAIR (MMR), BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY NON-HOMOLOGOUS END JOINING (NHEJ), BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY NUCLEOTIDE EXCISION REPAIR (NER), BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY RARE GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY CHEMOTHERAPY ENHANCERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SURGICAL ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SOLID, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 92. CANADA DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 93. CANADA DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 94. CANADA DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 95. CANADA DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 96. CANADA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 97. CANADA DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. CANADA DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. CANADA DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 100. CANADA DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 101. CANADA DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 102. CANADA DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 103. CANADA DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 104. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 105. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 106. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 107. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 108. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 109. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 110. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 112. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 113. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 114. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 115. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 129. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 130. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 136. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 140. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 142. AUSTRALIA DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 143. AUSTRALIA DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 144. AUSTRALIA DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 145. AUSTRALIA DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 146. AUSTRALIA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 147. AUSTRALIA DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. AUSTRALIA DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. AUSTRALIA DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 150. AUSTRALIA DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 151. AUSTRALIA DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 152. AUSTRALIA DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 153. AUSTRALIA DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 154. CHINA DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 155. CHINA DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 156. CHINA DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 157. CHINA DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 158. CHINA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 159. CHINA DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 160. CHINA DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. CHINA DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 162. CHINA DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 163. CHINA DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 164. CHINA DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 165. CHINA DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 166. INDIA DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 167. INDIA DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 168. INDIA DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 169. INDIA DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 170. INDIA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 171. INDIA DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 172. INDIA DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. INDIA DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 174. INDIA DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 175. INDIA DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 176. INDIA DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 177. INDIA DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 178. INDONESIA DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 179. INDONESIA DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 180. INDONESIA DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 181. INDONESIA DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 182. INDONESIA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 183. INDONESIA DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 184. INDONESIA DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. INDONESIA DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 186. INDONESIA DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 187. INDONESIA DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 188. INDONESIA DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 189. INDONESIA DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 190. JAPAN DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 191. JAPAN DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 192. JAPAN DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 193. JAPAN DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 194. JAPAN DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 195. JAPAN DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 196. JAPAN DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 197. JAPAN DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 198. JAPAN DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 199. JAPAN DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 200. JAPAN DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 201. JAPAN DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 202. MALAYSIA DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 203. MALAYSIA DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 204. MALAYSIA DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 205. MALAYSIA DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 206. MALAYSIA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 207. MALAYSIA DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 208. MALAYSIA DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 209. MALAYSIA DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 210. MALAYSIA DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 211. MALAYSIA DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 212. MALAYSIA DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 213. MALAYSIA DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 214. PHILIPPINES DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 215. PHILIPPINES DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 216. PHILIPPINES DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 217. PHILIPPINES DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 218. PHILIPPINES DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 219. PHILIPPINES DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 220. PHILIPPINES DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 221. PHILIPPINES DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 222. PHILIPPINES DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 223. PHILIPPINES DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 224. PHILIPPINES DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 225. PHILIPPINES DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 226. SINGAPORE DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 227. SINGAPORE DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 228. SINGAPORE DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 229. SINGAPORE DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 230. SINGAPORE DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 231. SINGAPORE DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 232. SINGAPORE DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 233. SINGAPORE DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 234. SINGAPORE DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 235. SINGAPORE DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 236. SINGAPORE DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 237. SINGAPORE DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 238. SOUTH KOREA DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 239. SOUTH KOREA DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 240. SOUTH KOREA DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 241. SOUTH KOREA DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 242. SOUTH KOREA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 243. SOUTH KOREA DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 244. SOUTH KOREA DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 245. SOUTH KOREA DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 246. SOUTH KOREA DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 247. SOUTH KOREA DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 248. SOUTH KOREA DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 249. SOUTH KOREA DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 250. TAIWAN DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 251. TAIWAN DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 252. TAIWAN DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 253. TAIWAN DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 254. TAIWAN DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 255. TAIWAN DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 256. TAIWAN DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 257. TAIWAN DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 258. TAIWAN DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 259. TAIWAN DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 260. TAIWAN DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 261. TAIWAN DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 262. THAILAND DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 263. THAILAND DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 264. THAILAND DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 265. THAILAND DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 266. THAILAND DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 267. THAILAND DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 268. THAILAND DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 269. THAILAND DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 270. THAILAND DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 271. THAILAND DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 272. THAILAND DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 273. THAILAND DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 274. VIETNAM DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 275. VIETNAM DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 276. VIETNAM DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 277. VIETNAM DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 278. VIETNAM DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 279. VIETNAM DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 280. VIETNAM DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 281. VIETNAM DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 282. VIETNAM DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 283. VIETNAM DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 284. VIETNAM DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 285. VIETNAM DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 295. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 296. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 297. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 298. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 299. DENMARK DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 300. DENMARK DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 301. DENMARK DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 302. DENMARK DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 303. DENMARK DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 304. DENMARK DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 305. DENMARK DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 306. DENMARK DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 307. DENMARK DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 308. DENMARK DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 309. DENMARK DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 310. DENMARK DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 311. EGYPT DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 312. EGYPT DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 313. EGYPT DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 314. EGYPT DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 315. EGYPT DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 316. EGYPT DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 317. EGYPT DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 318. EGYPT DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 319. EGYPT DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 320. EGYPT DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 321. EGYPT DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 322. EGYPT DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 323. FINLAND DNA REPAIR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 324. FINLAND DNA REPAIR DRUGS MARKET SIZE, BY CHECKPOINT KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 325. FINLAND DNA REPAIR DRUGS MARKET SIZE, BY DNA-PK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 326. FINLAND DNA REPAIR DRUGS MARKET SIZE, BY POLY ADP RIBOSE POLYMERASE (PARP) INHIBITORS, 2018-2030 (USD MILLION)
TABLE 327. FINLAND DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 328. FINLAND DNA REPAIR DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 329. FINLAND DNA REPAIR DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 330. FINLAND DNA REPAIR DRUGS MARKET SIZE, BY ONCOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 331. FINLAND DNA REPAIR DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 332. FINLAND DNA REPAIR DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 333. FINLAND DNA REPAIR DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 334. FINLAND DNA REPAIR DRUGS MARKET SIZE, BY CHEMICAL FORM, 2018-2030 (USD MILLION)
TABLE 335. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY DR

Companies Mentioned

  • Artios Pharma
  • AstraZeneca PLC
  • Aurigene Discovery Technologies
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • CanBas Co., Ltd.
  • Clovis Oncology
  • Corden Pharma International GmbH
  • Eli Lilly and Company
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Hanson Wade Group
  • Johnson & Johnson Services, Inc.
  • Merck KgaA
  • Novartis AG
  • Pfizer Inc.
  • Valerio Therapeutics

Methodology

Loading
LOADING...

Related Topics

Related Reports

DNA Repair Drugs - Global Strategic Business Report - Product Image

DNA Repair Drugs - Global Strategic Business Report

  • Report
  • 217 Pages
  • Global
From
DNA Repair Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

DNA Repair Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
DNA Repair Drugs Market Report 2025 - Product Image

DNA Repair Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
DNA Repair Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

DNA Repair Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 88 Pages
  • Global
From
Chromatin and Genomic Instability in Cancer. International Review of Cell and Molecular Biology Volume 364 - Product Image

Chromatin and Genomic Instability in Cancer. International Review of Cell and Molecular Biology Volume 364

  • Book
  • Global

About the DNA Repair Drug Market

The DNA Repair Drug market is a subset of the genomics industry that focuses on the development of drugs that can repair damaged DNA. These drugs are used to treat a variety of genetic diseases, including cancer, and can be used to prevent the onset of certain diseases. DNA repair drugs are typically administered through a variety of methods, including intravenous, oral, and topical applications. The DNA Repair Drug market is highly competitive, with a number of companies vying for market share. Companies in the market include AstraZeneca, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. These companies are actively researching and developing new drugs to treat genetic diseases, as well as exploring new methods of delivery. Additionally, many of these companies are investing in research and development to create more effective treatments for genetic diseases. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.